Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALK7-targeting RNAi
- Development stage
- Unknown
- Lead developer
- Alnylam Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ALK7-targeting RNAi therapies are small interfering RNA (siRNA) therapeutics designed to silence the expression of the ACVR1C gene, which encodes Activin receptor-like kinase 7 (ALK7). ALK7 is a type I receptor in the TGF-β superfamily predominantly expressed in adipose tissue that acts as a metabolic brake by suppressing lipolysis and promoting lipid storage. By silencing ALK7, these therapies promote lipid mobilization, increase catecholamine sensitivity, and reduce visceral adiposity while preserving lean mass, offering a novel approach for the treatment of obesity and metabolic diseases.
- Other names
- ACVR1C RNAiACVR-1C RNAiACVR 1C RNAiACVR1C siRNAACVR-1C siRNAACVR 1C siRNAACVR1C-targeting RNAiACVR-1C-targeting RNAiACVR 1C-targeting RNAiACVR1C-targeting siRNAACVR-1C-targeting siRNAACVR 1C-targeting siRNAALK7 RNAiALK-7 RNAiALK 7 RNAiALK7 siRNAALK-7 siRNAALK 7 siRNAALK7-targeting siRNAALK-7-targeting siRNAALK 7-targeting siRNA
02
Targets
ACVR1C (Activin A Receptor Type 1C)
Beyond the preview
Go deeper on ALK7-targeting RNAi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALK7-targeting RNAi.